- By ICR Secretariat
- Posted Thursday, April 28, 2022
How a surprise finding made an Alnylam study one of biotech’s most ‘polarizing’ trials
https://www.biopharmadive.com/news/alnylam-ttr-cardiomyopathy-apollo-bridge-bio-trial/622480/
The outcome, no longer seen as a sure bet, could influence how future drugs for a deadly heart disease are developed.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- NICE recommendation expands patient eligibility for AbbVie’s Ozurdex 18/08/2022 03:38 PM
- Amgen’s low tax rates draw attention of top Democratic senator 18/08/2022 03:23 PM
- 2 deaths after Novartis' Zolgensma put gene therapy's liver safety in the spotlight once again 18/08/2022 03:16 PM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org